"Is Wegovy still in shortage?" is one of those questions where the official answer and the lived experience don't quite match. The FDA closed the book on the national semaglutide shortage back in February 2025. But if you've called around to three or four pharmacies this month looking for your usual dose, you already know that "resolved" doesn't always mean "in stock at my CVS." This guide separates the two — what's officially true, what's actually happening at the pharmacy counter in mid-2026, and what to do about it either way.
1. Is Wegovy Officially "In Shortage"?
No. The FDA removed semaglutide injection products, including Wegovy and Ozempic, from its Drug Shortages Database on February 21, 2025, after Novo Nordisk moved to around-the-clock manufacturing and built up finished-product reserves following a multibillion-dollar expansion of production capacity, including the Catalent acquisition completed in late 2024.
But pharmacy-level data tells a messier story. Independent surveys of pharmacy stock throughout 2026 have found meaningful gaps — one early-2026 pharmacy survey found roughly a third of independent pharmacies and close to a fifth of chain locations had at least one Wegovy strength out of stock in a given week, with the 1.7 mg and 2.4 mg maintenance doses moving slowest through the supply chain since those are the strengths most long-term patients stay on.
In plain terms: this is not a repeat of the 2022–2024 shortage era, when patients regularly went without medication entirely. It's a distribution and demand-timing problem layered on top of a resolved manufacturing shortage — annoying and inconvenient, but generally solvable by checking a few different sources.
2. Why It's Still Hard to Find, Even After "Resolved"
A few forces are driving the gap between the official status and what patients experience:
- Demand keeps climbing. More prescribers are comfortable prescribing GLP-1 medications, and off-label weight-loss demand hasn't slowed even as manufacturing has caught up.
- Maintenance doses move unevenly. Patients titrate up over months, so starter doses (0.25 mg, 0.5 mg) turn over differently than the 1.7 mg and 2.4 mg doses most people eventually settle on long term — pharmacies don't always stock those in matching proportions.
- Compounding wind-down created a demand shock. When FDA compounding allowances expired in 2025, an estimated one to two million patients who had been on compounded semaglutide needed to shift to brand-name product, adding sudden pressure to the same supply chain.
- Distribution isn't perfectly even. A pharmacy's next delivery date, order size, and regional demand all affect whether your specific dose is on the shelf the day you walk in.
3. Timeline: How We Got Here
| Date | Event |
|---|---|
| 2022 | Semaglutide (Ozempic/Wegovy) shortage begins amid surging demand |
| 2022–2024 | Nationwide stockouts; FDA allows compounding pharmacies to produce copies |
| March 2024 | FDA approves Wegovy for cardiovascular risk reduction, opening a path to Medicare Part D coverage |
| Late 2024 | Novo Nordisk completes Catalent acquisition, adding fill-finish capacity |
| February 21, 2025 | FDA declares the semaglutide shortage officially resolved |
| April–May 2025 | FDA compounding grace periods expire; mass-market compounded semaglutide becomes largely illegal |
| December 2025 | FDA approves the oral Wegovy tablet (semaglutide 25 mg) |
| January 2026 | Oral Wegovy launches in U.S. pharmacies |
| March 19, 2026 | FDA approves Wegovy HD (semaglutide 7.2 mg), a higher maintenance dose, under the Commissioner's National Priority Voucher program |
| April 2026 | Wegovy HD launches in the U.S. in a single-dose pen |
| July 1, 2026 | Medicare GLP-1 Bridge program launches, covering Wegovy at $50/month for BMI-qualifying beneficiaries |
4. Current Availability by Dose
| Dose | Use | Typical 2026 availability |
|---|---|---|
| 0.25 mg | Starting dose | Generally available |
| 0.5 mg | Titration dose | Generally available |
| 1 mg | Titration dose | Generally available |
| 1.7 mg | Titration / near-maintenance dose | Intermittent gaps reported |
| 2.4 mg | Maintenance dose | Intermittent gaps reported |
| Wegovy HD (7.2 mg) | Higher maintenance dose | Launched April 2026; availability still building |
| Oral Wegovy tablet | Alternative to pen, all stages | Available since January 2026 |
Availability also varies meaningfully by pharmacy type and region — large chains tend to report fewer stockouts than independent pharmacies, and urban areas with more pharmacy options generally make it easier to find an alternate location with stock.
5. Oral Wegovy: The New Supply Pathway
The oral Wegovy tablet is a genuinely useful addition to the supply picture, not just a marketing footnote. Because it's manufactured through a different production process than the injectable pen, it represents additional capacity rather than competing demand on the same line. If your pharmacy is out of the pen strength you need, it's worth asking your prescriber whether the oral tablet is a reasonable option for you.
NovoCare Pharmacy self-pay pricing (2026): Oral Wegovy tablets run approximately $149 per month for the 1.5 mg and 4 mg doses through NovoCare's self-pay program (4 mg offer available through August 31, 2026, then $199/month). The injectable pen's self-pay rate is $199/month for 0.25 mg and 0.5 mg for new patients' first two fills, then $349/month for 0.25–2.4 mg or $399/month for Wegovy HD.
6. Wegovy vs Ozempic: Same Drug, Different Approval
Both Wegovy and Ozempic contain semaglutide and are made by Novo Nordisk. The active ingredient is identical. The difference is the FDA-approved use, the typical dose, and how insurance treats each one.
| Factor | Wegovy | Ozempic |
|---|---|---|
| FDA-approved use | Chronic weight management; cardiovascular risk reduction | Type 2 diabetes |
| Typical maintenance dose | 2.4 mg weekly (or 7.2 mg Wegovy HD) | 1 mg or 2 mg weekly |
| Insurance coverage | Often excluded; usually needs prior authorization or the Medicare Bridge | Usually covered for a diabetes diagnosis |
| Medicare coverage | Cardiovascular indication or GLP-1 Bridge | Part D with prior authorization |
| Manufacturer savings card | Available for commercially insured patients | Available for commercially insured patients |
| Patient assistance program | Novo Nordisk PAP (income-based) | Novo Nordisk PAP (income-based) |
Can my pharmacist substitute Ozempic for Wegovy? No. Because they carry different FDA-approved indications, pharmacies cannot auto-substitute one for the other — your prescriber has to write a new prescription. If you're considering a switch because of the Ozempic shortage guide or a coverage issue, see our Novo Nordisk patient assistance program guide for income limits and required documents.
7. Wegovy Savings Card and Patient Assistance
If your real barrier to Wegovy is cost, not supply, the Novo Nordisk savings card and patient assistance program are separate from the shortage discussion but directly determine whether you can actually fill your prescription.
| Program | Who qualifies | Monthly cost |
|---|---|---|
| Novo Nordisk savings card (commercial insurance) | Commercially insured patients | $0–$25 |
| NovoCare Pharmacy self-pay | No insurance required | $149–$399, dose-dependent |
| Novo Nordisk Patient Assistance Program | Uninsured, income-eligible | $0 for qualifying patients |
| Medicare GLP-1 Bridge | Medicare Part D, BMI criteria | Flat $50 |
Most patients don't realize: the Novo Nordisk Patient Assistance Program can provide Wegovy at no cost to income-eligible uninsured patients — a completely separate path from the commercial savings card. If you're uninsured and struggling with Wegovy's cost rather than its availability, the patient assistance program may serve you better than chasing pharmacy stock. See our full Novo Nordisk PAP guide for income limits and the required documents.
8. Alternatives If Your Pharmacy Is Out
If Wegovy specifically isn't available and you need to keep moving forward with treatment, these are the options typically discussed with a prescriber:
| Alternative | Active ingredient | Key consideration |
|---|---|---|
| Oral Wegovy tablet | Semaglutide (same as pen) | Different formulation of the same drug; separate supply chain |
| Zepbound | Tirzepatide | Different mechanism; requires a new prescription, not a direct swap |
| Saxenda | Liraglutide | Daily injection rather than weekly; different dosing schedule |
| Ozempic (off-label) | Semaglutide | Same drug as Wegovy but FDA-approved for diabetes, not weight loss; insurance may not cover off-label use |
None of these are interchangeable at the pharmacy counter — any switch needs your prescriber's input, both for dosing and for making sure your insurance will actually cover the substitute.
9. Eligibility Comparison: Wegovy Access Paths
| Pathway | Who qualifies |
|---|---|
| Commercial insurance | Depends entirely on your plan's formulary; many plans have narrowed or removed anti-obesity coverage |
| Medicare Part D — cardiovascular indication | Established cardiovascular disease (heart attack, stroke, symptomatic PAD) plus overweight/obesity |
| Medicare GLP-1 Bridge (from 7/1/2026) | BMI-based criteria set by CMS; plan must participate in the Bridge program |
| NovoCare Pharmacy self-pay | No insurance requirement; government beneficiaries excluded from the savings offer |
| Patient assistance program | Income-based eligibility; typically for uninsured or underinsured patients |
10. Cost and Income Comparison
| Path | Typical monthly cost | Income limit? |
|---|---|---|
| List price, no coverage | ~$1,349 | No |
| NovoCare Pharmacy self-pay (injectable) | $199–$399 depending on dose and tenure | No |
| NovoCare Pharmacy self-pay (oral) | ~$149–$199 depending on dose | No |
| Commercial insurance with savings card | As low as $0–$25 | No, but plan coverage required |
| Medicare Part D (cardiovascular indication) | $250–$400+ before OOP cap; $0 after reaching the $2,100 annual cap | No |
| Medicare GLP-1 Bridge | Flat $50/month | BMI-based clinical criteria, not income |
| Patient assistance program | $0 for qualifying patients | Yes — household income limits apply |
Notice that most of the newer 2026 access paths — self-pay, the GLP-1 Bridge — are not income-tested. If you don't qualify for any of them, a traditional patient assistance program is still the option most likely to bring the cost to $0, but it does require documenting household income.
11. Covered Medications by Pathway
| Pathway | Wegovy injectable | Oral Wegovy | Other GLP-1s |
|---|---|---|---|
| Medicare Part D (CV indication) | Yes | Plan-dependent | Ozempic/Mounjaro covered for diabetes only |
| Medicare GLP-1 Bridge | Yes | Yes | Bridge covers Wegovy specifically |
| NovoCare Pharmacy | Yes | Yes | Also covers Ozempic; Saxenda not eligible for delivery |
| Commercial insurance | Plan-dependent | Plan-dependent | Varies widely by employer plan |
12. Step-by-Step: What to Do If You Can't Find It
Confirm what's actually out of stock
Ask your pharmacy specifically which dose and formulation they're missing — sometimes only one strength is affected while others are sitting on the shelf.
Check a few nearby pharmacies
Availability varies by chain and by individual location, so calling two or three nearby options before assuming it's unavailable citywide is worth the ten minutes.
Ask your prescriber about the oral tablet
If the pen is out but you're a reasonable candidate for the tablet, this can keep you on treatment without a gap.
Consider NovoCare Pharmacy for self-pay delivery
If insurance coverage — not just physical stock — is your real obstacle, NovoCare Pharmacy's self-pay pricing may be more predictable than chasing retail stock month to month.
Confirm insurance coverage before switching anything
Before accepting a substitute medication, check whether your plan actually covers it — a prior authorization denial on the alternative can leave you worse off than waiting a few extra days for your usual dose.
Never stop treatment abruptly without guidance
If you're at risk of a real gap, contact your prescriber's office rather than simply stopping — they may have guidance specific to your dose and duration of treatment.
13. Approval and Delivery Timelines
| Path | Typical timeline |
|---|---|
| Retail pharmacy pickup (in stock) | Same day |
| Retail pharmacy special order | 1–7 business days, pharmacy-dependent |
| NovoCare Pharmacy home delivery | Under 1 week after payment, typically |
| Commercial insurance prior authorization | 3–14 business days |
| Medicare Part D (CV indication) prior authorization | Up to 14 business days |
| Medicare GLP-1 Bridge enrollment | Varies by plan; confirm participation before assuming eligibility |
14. Renewal and Staying on Treatment
Because Wegovy is typically a long-term maintenance medication, staying ahead of renewals matters as much as finding your first fill:
- Track your remaining refills and reach out to your prescriber's office before you run out, not after.
- If you're using Medicare Part D under the cardiovascular indication, your documentation needs to stay current in your medical record for continued coverage.
- If you're using the GLP-1 Bridge program, remember it runs only through December 31, 2027 — plan for what happens to your coverage afterward rather than assuming it continues indefinitely.
- If your plan changes for a new benefit year, re-confirm Wegovy is still on the formulary and that any prior authorization carries over or needs to be resubmitted.
15. Common Mistakes to Avoid
Mistakes patients make
- Assuming "shortage resolved" means every dose is always in stock everywhere
- Turning to compounded semaglutide without confirming it's still legally available to them
- Switching to a different GLP-1 without checking insurance coverage first
- Not asking about the oral tablet when the pen is unavailable
- Letting a Medicare GLP-1 Bridge enrollment lapse without a plan for 2028
What works well
- Calling ahead before a scheduled refill instead of showing up unannounced
- Asking pharmacies specifically which dose is affected, not just "is Wegovy in stock"
- Comparing NovoCare self-pay pricing against your insurance copay before deciding
- Keeping your prescriber informed about supply issues so they can pivot quickly
- Checking Medicare Bridge plan participation before counting on the $50 copay
16. Pros and Cons of Each Access Path
NovoCare Pharmacy self-pay
- No insurance needed; predictable flat pricing
- Free home delivery, tracked shipping
- Both pen and tablet available through the same channel
NovoCare Pharmacy self-pay
- Government beneficiaries excluded from the savings rate
- Still a real monthly cost without insurance help
- New-patient pricing steps up after the first two fills
Medicare GLP-1 Bridge
- Flat $50/month regardless of list price
- No cardiovascular diagnosis required
- Covers both the pen and oral tablet
Medicare GLP-1 Bridge
- Temporary program, ending December 31, 2027
- Doesn't count toward your Part D out-of-pocket cap
- Requires your specific plan to participate
17. Decision Tree: What Should You Do Right Now?
Either option can keep you on treatment without the gap — confirm insurance coverage or self-pay pricing before switching.
Related: Ozempic Mail Order: How to Get It Delivered in 2026
NovoCare Pharmacy ships Ozempic too — see how the delivery process and pricing work.
Need help paying for Wegovy or other GLP-1 medications?